Giao dịch PURETECH HEALTH PLC ORD 1P - PRTC CFD

Điều kiện giao dịch

• Loại: CFD
• Chênh lệch: 0.0110
• Điều chỉnh phí tài trợ qua đêm cho vị thế mua: -0.02126%
• Điều chỉnh phí tài trợ qua đêm cho vị thế bán: -0.00066%
• Thời gian điều chỉnh phí tài trợ qua đêm: 22:00 (UTC)
• Tiền tệ: GBP
• Số lượng giao dịch tối thiểu: 10
• Biên lợi nhuận: 5.00%
• Sàn giao dịch chứng khoán: United Kingdom of Great Britain and Northern Ireland
• Phí hoa hồng giao dịch: 0%
• Bảo đảm dừng phí bảo hiểm: 1%

Số liệu thống kê chính

• Trước đó Đóng: 1.3405
• Mở: 1.3125
• Thay đổi 1 năm: -5.34%
• Phạm vi trong ngày: 1.3125 - 1.3385

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer''s; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer''s disease, multiple sclerosis, and Parkinson''s disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company''s medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts.